Madrigal 3196-18 A 52-Week, Phase 3 Open-Label Extension Study, with a Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Madrigal Pharmaceuticals, Inc.
Start Date
March 24, 2022
End Date
February 27, 2025
Administered By
Medicine, Gastroenterology
Awarded By
Madrigal Pharmaceuticals, Inc.
Start Date
March 24, 2022
End Date
February 27, 2025